Navigation Links
PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/10/2008

ANNAPOLIS, Md., March 10 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the Cowen and Company 28th Annual Health Care Conference in Boston on Tuesday, March 18, 2008 at 8:45 a.m. The presentation is scheduled to take place in the Vineyard Room at the Boston Marriott Copley Place hotel.

PharmAthene's presentation will be available via webcast on the company's website at http://www.pharmathene.com. A link to access the webcast will be accessible from both the homepage and the investor relations pages of the PharmAthene corporate website. For assistance, contact Stacey Jurchison at 410-269-2610.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2